<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326622</url>
  </required_header>
  <id_info>
    <org_study_id>FCT - SFRH/BD/78413/2011</org_study_id>
    <nct_id>NCT03326622</nct_id>
  </id_info>
  <brief_title>Exercise and Disease Progression in Amyotrophic Lateral Sclerosis Patients</brief_title>
  <official_title>The Role of Moderate Aerobic Exercise as Determined by Cardiopulmonary Exercise Testing in ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lisbon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Lisbon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the influence of a tailored aerobic exercise protocol on the functional
      outcome in ALS patients. In addition, the investigators compare some CPET variables collected
      during exercise testing in both groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This work aimed to evaluate the effects of a moderate aerobic exercise with controlled
      intensity determined by Cardiopulmonary Exercise Testing (CPET) and its role on the
      functional status in ALS patients versus standard care. Additionally, the investigators
      explored the performance of CPET variables - oxygen uptake (VO2) expressed in L/min, in
      percentage of predicted or in metabolic equivalents (METs) at peak effort, at anaerobic
      threshold (AT), the respiratory compensation point (RCP) when achieved, Dioxide Carbon output
      in L/min (VCO2) and the minute ventilation in L/min (VE) throughout the study.

      Assessments:(diagnostic visit - T0), at study entry (T1) and 6 months after (T2) using:

      Functional status by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised
      (ALSFRS-R), Respiratory function tests (RFT): Forced Vital Capacity predicted (%FVC) and
      Oxygen saturation provided by pulse oximetry.

      CPET was performed in both groups at study entry and 6 months later (T1 and T2), using a
      treadmill (WOODWAY®) coupled with a gas exchange analyzer (METALYZER® 3B) with
      ergo-spirometry system using a breath-by-breath technology developed by CORTEX® systems.

      Intervention:

      G1(Interventional group) performed moderate exercise protocol two times/week in a treadmill
      in the lower range of the training zone determined by CPET + standard care (range of motion
      exercise, gait and balance training under continuous pulse oximetry observation).

      G2 (control group) performed a standard care exercise program at home or at other
      rehabilitation units without pulse oximetry observation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2013</start_date>
  <completion_date type="Actual">June 30, 2015</completion_date>
  <primary_completion_date type="Actual">March 30, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>single blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Functional decline between start and end of the study</measure>
    <time_frame>between baseline and 6 months later</time_frame>
    <description>It was used the Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R),which rates the functionality of the ALS patients in performing activities involving 4 different areas through 3 sub-scores - bulbar, spinal [upper and lower limb] and also the respiratory function. Each of its questions is rated from 0 (total inability) to 4 points (no functional limitation). The last three questions address the respiratory function (dyspnea, orthopnea, respiratory insufficiency) and assess the respiratory functional outcome.
The sub-scores rating: Bulbar sub-score between 0 - 12, the spinal score between 0 - 24 and the respiratory sub-score between 0 - 12.The sum of the sub-scores provide an ALSFRS-R total score = 48. Higher values represent a better functionality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance of Cardiopulmonary Exercise testing variables throughout the study</measure>
    <time_frame>at study entry and 6 months later.</time_frame>
    <description>Changes on the oxygen uptake (VO2peak) measurement following an aerobic exercise protocol compared to standard care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on the Dioxide Carbon output (VCO2) measurement</measure>
    <time_frame>at study entry and 6 months later</time_frame>
    <description>Changes on the Dioxide Carbon output (VCO2) following an aerobic exercise protocol compared to standard care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on the Minute Ventilation (VE) measurement</measure>
    <time_frame>at study entry and 6 months later</time_frame>
    <description>Changes on Minute ventilation (VE) following an aerobic exercise protocol compared to standard care.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>moderate exercise + standard care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group performed a moderate exercise protocol with training zone determined by Cardiopulmonary Exercise testing added to standard care program based on American Academy of Neurology guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group performed a standard care program based on American Academy of Neurology guidelines, without exercise intensity control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care</intervention_name>
    <description>A standard care program based on American Academy of Neurology guidelines (Range Of Motion (ROM) exercises, gait and balance training )at home or another rehabilitation units without intensity control.</description>
    <arm_group_label>moderate exercise + standard care</arm_group_label>
    <arm_group_label>Standard care</arm_group_label>
    <other_name>Range of Motion</other_name>
    <other_name>Gait Training</other_name>
    <other_name>Balance training</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>moderate exercise</intervention_name>
    <description>A moderate exercise protocol two times per week in a treadmill in the lower range of the training zone determined by Cardiopulmonary Exercise Testing, monitored by continuous pulse oximetry evaluation.</description>
    <arm_group_label>moderate exercise + standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive patients diagnosed with definite, probable, or probable laboratory
             supported ALS

          -  Disease duration from first symptoms between 6-24 months to exclude slow and fast
             progression

          -  ALSFRS-R ≥ 30

          -  FVC (%predicted) ≥ 70%

        Exclusion Criteria:

          -  Other medical conditions, like cardiac insufficiency and lung disorders or others
             conditions limiting exercise training;

          -  Heavy smoking habits with laboratorial evidence of significant bronchial constriction;

          -  Signs of associated dementia or psychiatric disorders.

        Note: None of the patients were on tube feeding, invasive or non-invasive mechanical
        ventilation at admission of study protocol (T1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mamede de Carvalho, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Molecular Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anabela Pinto, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Molecular Medicine</affiliation>
  </overall_official>
  <reference>
    <citation>World Health Organization - Physical activity Fact Sheet nº385. In www.who.int/mediacentre/factsheets/fs385/en/ January; 2015</citation>
  </reference>
  <reference>
    <citation>Mahoney DJ, Rodriguez C, Devries M, Yasuda N, Tarnopolsky MA. Effects of high-intensity endurance exercise training in the G93A mouse model of amyotrophic lateral sclerosis. Muscle Nerve. 2004 May;29(5):656-62.</citation>
    <PMID>15116368</PMID>
  </reference>
  <reference>
    <citation>Pinto S, Swash M, de Carvalho M. Respiratory exercise in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012 Jan;13(1):33-43. doi: 10.3109/17482968.2011.626052.</citation>
    <PMID>22214352</PMID>
  </reference>
  <reference>
    <citation>Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, Forman D, Franklin B, Guazzi M, Gulati M, Keteyian SJ, Lavie CJ, Macko R, Mancini D, Milani RV; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Interdisciplinary Council on Quality of Care and Outcomes Research. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010 Jul 13;122(2):191-225. doi: 10.1161/CIR.0b013e3181e52e69. Epub 2010 Jun 28. Review.</citation>
    <PMID>20585013</PMID>
  </reference>
  <reference>
    <citation>Binder RK, Wonisch M, Corra U, Cohen-Solal A, Vanhees L, Saner H, Schmid JP. Methodological approach to the first and second lactate threshold in incremental cardiopulmonary exercise testing. Eur J Cardiovasc Prev Rehabil. 2008 Dec;15(6):726-34. doi: 10.1097/HJR.0b013e328304fed4. Review.</citation>
    <PMID>19050438</PMID>
  </reference>
  <reference>
    <citation>Majmudar S, Wu J, Paganoni S. Rehabilitation in amyotrophic lateral sclerosis: why it matters. Muscle Nerve. 2014 Jul;50(1):4-13. doi: 10.1002/mus.24202. Epub 2014 May 17. Review.</citation>
    <PMID>24510737</PMID>
  </reference>
  <reference>
    <citation>Cup EH, Pieterse AJ, Ten Broek-Pastoor JM, Munneke M, van Engelen BG, Hendricks HT, van der Wilt GJ, Oostendorp RA. Exercise therapy and other types of physical therapy for patients with neuromuscular diseases: a systematic review. Arch Phys Med Rehabil. 2007 Nov;88(11):1452-64. Review.</citation>
    <PMID>17964887</PMID>
  </reference>
  <reference>
    <citation>Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol. 1992 Feb;31(2):119-30. Review.</citation>
    <PMID>1349466</PMID>
  </reference>
  <reference>
    <citation>Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009 Oct 13;73(15):1218-26. doi: 10.1212/WNL.0b013e3181bc0141. Review. Erratum in: Neurology. 2010 Mar 2;74(9):781. Neurology. 2009 Dec 15;73(24):2134.</citation>
    <PMID>19822872</PMID>
  </reference>
  <reference>
    <citation>Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luís ML. Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci. 1995 May;129 Suppl:19-26.</citation>
    <PMID>7595610</PMID>
  </reference>
  <reference>
    <citation>Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006 Feb;5(2):140-7.</citation>
    <PMID>16426990</PMID>
  </reference>
  <reference>
    <citation>Chetta A, Aiello M, Tzani P, Olivieri D. Assessment and monitoring of ventilatory function and cough efficacy in patients with amyotrophic lateral sclerosis. Monaldi Arch Chest Dis. 2007 Mar;67(1):43-52. Review.</citation>
    <PMID>17564284</PMID>
  </reference>
  <reference>
    <citation>Centre for Clinical Practice at NICE (UK). Motor Neurone Disease: The Use of Non-Invasive Ventilation in the Management of Motor Neurone Disease [Internet]. London: National Institute for Health and Clinical Excellence (UK); 2010 Jul. Available from http://www.ncbi.nlm.nih.gov/books/NBK65383/</citation>
    <PMID>22171400</PMID>
  </reference>
  <reference>
    <citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999 Oct 31;169(1-2):13-21.</citation>
    <PMID>10540002</PMID>
  </reference>
  <reference>
    <citation>Pinto A, de Carvalho M, Evangelista T, Lopes A, Sales-Luís L. Nocturnal pulse oximetry: a new approach to establish the appropriate time for non-invasive ventilation in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Apr;4(1):31-5.</citation>
    <PMID>12745616</PMID>
  </reference>
  <reference>
    <citation>EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis:, Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, Hardiman O, Kollewe K, Morrison KE, Petri S, Pradat PF, Silani V, Tomik B, Wasner M, Weber M. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur J Neurol. 2012 Mar;19(3):360-75. doi: 10.1111/j.1468-1331.2011.03501.x. Epub 2011 Sep 14.</citation>
    <PMID>21914052</PMID>
  </reference>
  <reference>
    <citation>Wasserman K, Hansen JE, Sue DY, Stringer WW, Sietsema KE, Sun X-G, Whipp BJ.Principles of Exercise Testing and Interpretation: Including Pathophysiology and Clinical Applications, 5th edn; eds (2012). Lippincott Williams &amp; Wilkins, Philadelphia, USA.ISBN 978-1-60913-899-8</citation>
  </reference>
  <reference>
    <citation>American Thoracic Society/European Respiratory Society. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med. 2002 Aug 15;166(4):518-624.</citation>
    <PMID>12186831</PMID>
  </reference>
  <reference>
    <citation>Vucic S, Krishnan AV, Kiernan MC. Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2007 Nov;78(11):1202-8. Epub 2007 Mar 19.</citation>
    <PMID>17371901</PMID>
  </reference>
  <reference>
    <citation>Longstreth WT, Nelson LM, Koepsell TD, van Belle G. Hypotheses to explain the association between vigorous physical activity and amyotrophic lateral sclerosis. Med Hypotheses. 1991 Feb;34(2):144-8.</citation>
    <PMID>2041488</PMID>
  </reference>
  <reference>
    <citation>Anand A, Thakur K, Gupta PK. ALS and oxidative stress: the neurovascular scenario. Oxid Med Cell Longev. 2013;2013:635831. doi: 10.1155/2013/635831. Epub 2013 Dec 3. Review.</citation>
    <PMID>24367722</PMID>
  </reference>
  <reference>
    <citation>Sanjak M, Paulson D, Sufit R, Reddan W, Beaulieu D, Erickson L, Shug A, Brooks BR. Physiologic and metabolic response to progressive and prolonged exercise in amyotrophic lateral sclerosis. Neurology. 1987 Jul;37(7):1217-20.</citation>
    <PMID>3601086</PMID>
  </reference>
  <reference>
    <citation>Mezzani A, Pisano F, Cavalli A, Tommasi MA, Corrà U, Colombo S, Grassi B, Marzorati M, Porcelli S, Morandi L, Giannuzzi P. Reduced exercise capacity in early-stage amyotrophic lateral sclerosis: Role of skeletal muscle. Amyotroph Lateral Scler. 2012 Jan;13(1):87-94. doi: 10.3109/17482968.2011.601463. Epub 2011 Aug 11.</citation>
    <PMID>21830991</PMID>
  </reference>
  <reference>
    <citation>Siciliano G, D'Avino C, Del Corona A, Barsacchi R, Kusmic C, Rocchi A, Pastorini E, Murri L. Impaired oxidative metabolism and lipid peroxidation in exercising muscle from ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002 Jun;3(2):57-62.</citation>
    <PMID>12215226</PMID>
  </reference>
  <reference>
    <citation>Battista RA, Foster C, Andrew J, Wright G, Lucia A, Porcari JP. Physiologic responses during indoor cycling. J Strength Cond Res. 2008 Jul;22(4):1236-41. doi: 10.1519/JSC.0b013e318173dbc4.</citation>
    <PMID>18545183</PMID>
  </reference>
  <reference>
    <citation>Hill DW, Rowell AL. Significance of time to exhaustion during exercise at the velocity associated with VO2max. Eur J Appl Physiol Occup Physiol. 1996;72(4):383-6.</citation>
    <PMID>8851910</PMID>
  </reference>
  <reference>
    <citation>Lunetta C, Lizio A, Sansone VA, Cellotto NM, Maestri E, Bettinelli M, Gatti V, Melazzini MG, Meola G, Corbo M. Strictly monitored exercise programs reduce motor deterioration in ALS: preliminary results of a randomized controlled trial. J Neurol. 2016 Jan;263(1):52-60.</citation>
    <PMID>26477027</PMID>
  </reference>
  <reference>
    <citation>Blizzard CA, Southam KA, Dawkins E, Lewis KE, King AE, Clark JA, Dickson TC. Identifying the primary site of pathogenesis in amyotrophic lateral sclerosis - vulnerability of lower motor neurons to proximal excitotoxicity. Dis Model Mech. 2015 Mar;8(3):215-24. doi: 10.1242/dmm.018606.</citation>
    <PMID>25740331</PMID>
  </reference>
  <reference>
    <citation>Carilho R, de Carvalho M, Swash M, Pinto S, Pinto A, Costa J. Vascular endothelial growth factor and amyotrophic lateral sclerosis: the interplay with exercise and noninvasive ventilation. Muscle Nerve. 2014 Apr;49(4):545-50. doi: 10.1002/mus.23955.</citation>
    <PMID>23868282</PMID>
  </reference>
  <reference>
    <citation>Takken T, Groen WG, Hulzebos EH, Ernsting CG, van Hasselt PM, Prinsen BH, Helders PJ, Visser G. Exercise stress testing in children with metabolic or neuromuscular disorders. Int J Pediatr. 2010;2010. pii: 254829. doi: 10.1155/2010/254829. Epub 2010 Jul 15.</citation>
    <PMID>20706686</PMID>
  </reference>
  <reference>
    <citation>Lanfranconi F, Ferri A, Corna G, Bonazzi R, Lunetta C, Silani V, Riva N, Rigamonti A, Maggiani A, Ferrarese C, Tremolizzo L. Inefficient skeletal muscle oxidative function flanks impaired motor neuron recruitment in Amyotrophic Lateral Sclerosis during exercise. Sci Rep. 2017 Jun 7;7(1):2951. doi: 10.1038/s41598-017-02811-z.</citation>
    <PMID>28592858</PMID>
  </reference>
  <reference>
    <citation>Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clin Investig (Lond). 2014;4(7):605-618.</citation>
    <PMID>28203356</PMID>
  </reference>
  <reference>
    <citation>Dal Bello-Haas V, Florence JM. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2013 May 31;(5):CD005229. doi: 10.1002/14651858.CD005229.pub3. Review.</citation>
    <PMID>23728653</PMID>
  </reference>
  <reference>
    <citation>Pinto AC, Alves M, Nogueira A, Evangelista T, Carvalho J, Coelho A, de Carvalho M, Sales-Luís ML. Can amyotrophic lateral sclerosis patients with respiratory insufficiency exercise? J Neurol Sci. 1999 Oct 31;169(1-2):69-75.</citation>
    <PMID>10540010</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lisbon</investigator_affiliation>
    <investigator_full_name>Anna Caroline Braga</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>aerobic exercise</keyword>
  <keyword>functional outcome</keyword>
  <keyword>non-invasive ventilation</keyword>
  <keyword>oxygen uptake</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

